Johnson PC, Gainor JF, Sullivan RJ, Longo DL, Chabner B. Immune checkpoint inhibitors—the need for innovation. N Engl J Med. 2023;388:1529–32.

Article  PubMed  Google Scholar 

Rosenberg SA, Restifo NP. Adoptive cell transfer as personalized immunotherapy for human cancer. Science. 2015;348:62–8.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gross G, Waks T, Eshhar Z. Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity. Proc Natl Acad Sci U S A. 1989;86:10024–8.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Eshhar Z, Waks T, Gross G, Schindler DG. Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors. Proc Natl Acad Sci U S A. 1993;90:720–4.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kuwana Y, Asakura Y, Utsunomiya N, Nakanishi M, Arata Y, Itoh S, et al. Expression of chimeric receptor composed of immunoglobulin-derived V regions and T-cell receptor-derived C regions. Biochem Biophys Res Commun. 1987;149:960–8.

Article  CAS  PubMed  Google Scholar 

Labanieh L, Mackall CL. CAR immune cells: design principles, resistance and the next generation. Nature. 2023;614:635–48.

Article  CAS  PubMed  Google Scholar 

Cappell KM, Kochenderfer JN. Long-term outcomes following CAR T cell therapy: what we know so far. Nat Rev Clin Oncol. 2023;20:359–71.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cappell KM, Sherry RM, Yang JC, Goff SL, Vanasse DA, McIntyre L, et al. Long-term follow-up of anti-CD19 chimeric antigen receptor T-cell therapy. J Clin Oncol. 2020;38:3805–15.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hu D, Chen L, Yan D, Dong W, Chen M, Niu S, et al. Effectiveness and safety of anti-BCMA chimeric antigen receptor T-cell treatment in relapsed/refractory multiple myeloma: a comprehensive review and meta-analysis of prospective clinical trials. Front Pharmacol. 2023;14:1149138.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Neelapu SS, Tummala S, Kebriaei P, Wierda W, Gutierrez C, Locke FL, et al. Chimeric antigen receptor T-cell therapy - assessment and management of toxicities. Nat Rev Clin Oncol. 2018;15:47–62.

Article  CAS  PubMed  Google Scholar 

Fajgenbaum DC, June CH. Cytokine storm. N Engl J Med. 2020;383:2255–73.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yang C, Nguyen J, Yen Y. Complete spectrum of adverse events associated with chimeric antigen receptor (CAR)-T cell therapies. J Biomed Sci. 2023;30:89.

Article  PubMed  PubMed Central  Google Scholar 

Morris EC, Neelapu SS, Giavridis T, Sadelain M. Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy. Nat Rev Immunol. 2022;22:85–96.

Article  CAS  PubMed  Google Scholar 

Baker DJ, Arany Z, Baur JA, Epstein JA, June CH. CAR T therapy beyond cancer: the evolution of a living drug. Nature. 2023;619:707–15.

Article  CAS  PubMed  Google Scholar 

Maalej KM, Merhi M, Inchakalody VP, Mestiri S, Alam M, Maccalli C, et al. CAR-cell therapy in the era of solid tumor treatment: current challenges and emerging therapeutic advances. Mol Cancer. 2023;22:20.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chang Y, Cai X, Syahirah R, Yao Y, Xu Y, Jin G, et al. CAR-neutrophil mediated delivery of tumor-microenvironment responsive nanodrugs for glioblastoma chemo-immunotherapy. Nat Commun. 2023;14:2266.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Landoni E, Woodcock MG, Barragan G, Casirati G, Cinella V, Stucchi S, et al. IL-12 reprograms CAR-expressing natural killer T cells to long-lived Th1-polarized cells with potent antitumor activity. Nat Commun. 2024;15:89.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Schett G, Mackensen A, Mougiakakos D. CAR T-cell therapy in autoimmune diseases. Lancet. 2023;402:2034–44.

Article  CAS  PubMed  Google Scholar 

Berrien-Elliott MM, Jacobs MT, Fehniger TA. Allogeneic natural killer cell therapy. Blood. 2023;141:856–68.

Article  CAS  PubMed  Google Scholar 

Finck AV, Blanchard T, Roselle CP, Golinelli G, June CH. Engineered cellular immunotherapies in cancer and beyond. Nat Med. 2022;28:678–89.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hofer E, Koehl U. Natural killer cell-based cancer immunotherapies: from immune evasion to promising targeted cellular therapies. Front Immunol. 2017;8:745.

Article  PubMed  PubMed Central  Google Scholar 

Terrén I, Orrantia A, Mikelez-Alonso I, Vitallé J, Zenarruzabeitia O, Borrego F. NK cell-based immunotherapy in renal cell carcinoma. Cancers. 2020;12:316.

Article  PubMed  PubMed Central  Google Scholar 

Liu E, Tong Y, Dotti G, Shaim H, Savoldo B, Mukherjee M, et al. Cord blood NK cells engineered to express IL-15 and a CD19-targeted CAR show long-term persistence and potent antitumor activity. Leukemia. 2018;32:520–31.

Article  CAS  PubMed  Google Scholar 

Liu E, Marin D, Banerjee P, Macapinlac HA, Thompson P, Basar R, et al. Use of CAR-transduced natural killer cells in CD19-positive lymphoid tumors. N Engl J Med. 2020;382:545–53.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhang Y, Zhou W, Yang J, Yang J, Wang W. Chimeric antigen receptor engineered natural killer cells for cancer therapy. Exp Hematol Oncol. 2023;12:70.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wang X, Yang X, Yuan X, Wang W, Wang Y. Chimeric antigen receptor-engineered NK cells: new weapons of cancer immunotherapy with great potential. Exp Hematol Oncol. 2022;11:85.

Article  PubMed  PubMed Central  Google Scholar 

Shi Y, Hao D, Qian H, Tao Z. Natural killer cell-based cancer immunotherapy: from basics to clinical trials. Exp Hematol Oncol. 2024;13:101.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Biederstädt A, Rezvani K. Engineering the next generation of CAR-NK immunotherapies. Int J Hematol. 2021;114:554–71.

Article  PubMed  PubMed Central  Google Scholar 

Laskowski TJ, Biederstädt A, Rezvani K. Natural killer cells in antitumour adoptive cell immunotherapy. Nat Rev Cancer. 2022;22:557–75.

Article  CAS  PubMed  PubMed Central